BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

They are careful to avoid definitive statements about clinically meaningful benefits. There’s also this statement at the bottom:
Statistical Note
Unless otherwise noted, all p-values reported in this release are nominal and unadjusted for multiplicity, consistent with the exploratory, signal-finding objectives of this Phase 2 study.
They tested a lot of things.
 
Back
Top Bottom